RecruitingNCT04536220
Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer
Establish a Diagnostic Model Based on Multiple Molecule Profiling and Certain Established Markers for Identification of Pancreatic Cancer
Sponsor
Changhai Hospital
Enrollment
300 participants
Start Date
Jan 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Explore new markers based on portal venous blood sampling to establish novel diagnostic models for identification of malignant pancreatic mass.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria4
- age 18-75 years,male or female
- diagnosis or suspection of solid pancreatic mass based on previous imaging examination (ultrasonography, CT or MRI)
- lesion diameter larger than 1 cm
- signed informed consent letter
Exclusion Criteria8
- pregnant female
- Pancreatic cystic lesions
- Anticoagulant/antiplatelet therapy cannot be suspended
- unable or refuse to provide informed consent
- Coagulopathy (platelet count < 50× 103/μL,international normalized ratio > 1.5)
- Severe cardiopulmonary dysfunction that cannot tolerate intravenous anesthesia
- with history of mental disease
- other medical conditions that are not suitable for EUS-FNA
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTEndoscopic Ultrasound (EUS), Fine Needle Aspiration
Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04536220